Dimensional Fund Advisors LP acquired a new stake in VBI Vaccines Inc (NASDAQ:VBIV) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 80,962 shares of the biopharmaceutical company’s stock, valued at approximately $223,000. Dimensional Fund Advisors LP owned about 0.13% of VBI Vaccines as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of VBIV. Menora Mivtachim Holdings LTD. boosted its stake in shares of VBI Vaccines by 27.4% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 3,459,868 shares of the biopharmaceutical company’s stock valued at $9,515,000 after purchasing an additional 744,706 shares during the last quarter. General American Investors Co. Inc. boosted its stake in shares of VBI Vaccines by 44.1% in the 2nd quarter. General American Investors Co. Inc. now owns 864,464 shares of the biopharmaceutical company’s stock valued at $2,377,000 after purchasing an additional 264,464 shares during the last quarter. LMR Partners LLP bought a new stake in shares of VBI Vaccines in the 2nd quarter valued at $233,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of VBI Vaccines by 7.3% in the 1st quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock valued at $1,720,000 after purchasing an additional 33,588 shares during the last quarter. 48.00% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently commented on VBIV shares. Zacks Investment Research lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, September 28th. BMO Capital Markets reduced their price objective on shares of VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. VBI Vaccines has an average rating of “Hold” and an average target price of $9.08.
Shares of NASDAQ VBIV opened at $1.73 on Thursday. VBI Vaccines Inc has a 12-month low of $1.64 and a 12-month high of $5.10. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 0.14.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Read More: What is the 52-week high/low?
Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc (NASDAQ:VBIV).
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.